SHIFA BIOMEDICAL CORPORATION

Basic Information

GREAT VALLEY CORPORATE CENTER
MALVERN, PA, 19355-1423

Company Profile

n/a

Additional Details

Field Value
DUNS: 192526221
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 7


  1. Novel Modulators of LDL Metabolism

    Amount: $1,000,000.00

    DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is well-know ...

    SBIR Phase II 2014 Department of Health and Human Services
  2. Novel Modulators of LDL Metabolism

    Amount: $1,000,000.00

    DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well know ...

    SBIR Phase II 2014 Department of Health and Human Services National Institutes of Health
  3. Novel Modulators of HDL Metabolism

    Amount: $1,539,615.00

    Project Summary/Abstract Cardiovascular disease remains the leading cause of morbidity and mortality for both men and women, accounting for nearly 40% of annual deaths. High levels of LDL-C and low l ...

    SBIR Phase II 2012 Department of Health and Human Services
  4. A Novel Cassette System for the Assembly of VLP Vaccines

    Amount: $296,731.00

    DESCRIPTION (provided by applicant): Influenza and other infectious diseases are a major cause of death in the US and world-wide. Vaccination is the most cost-effective strategy to prevent these disea ...

    SBIR Phase I 2012 Department of Health and Human Services
  5. Novel Self-Limiting Prothrombinase Inhibitors

    Amount: $347,218.00

    Project Summary/Abstract Thrombosis is a primary cause of death in the US and developed world. Fatal or debilitating blood clots occur in the three major diseases of the western world: heart attacks, ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Structure-Based Search for Novel Antihypercholestrolemic Agent

    Amount: $1,336,680.00

    DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is well-know ...

    SBIR Phase II 2010 Department of Health and Human Services
  7. Structure-Based Design of Novel HNF4a Antagonists to Treat Metabolic Syndrome

    Amount: $290,230.00

    DESCRIPTION (provided by applicant): The long-term goal of this work is to develop novel drugs for the treatment of metabolic syndrome (MetS). MetS is an assemblage of associated clinical disorders re ...

    SBIR Phase I 2010 Department of Health and Human Services
  8. Novel Modulators of LDL Metabolism

    Amount: $258,591.00

    DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is a well-kn ...

    SBIR Phase I 2009 Department of Health and Human Services
  9. Novel Modulators of HDL Metabolism

    Amount: $270,518.00

    DESCRIPTION (provided by applicant): Cardiovascular disease remains the leading cause of morbidity and mortality for both men and women, accounting for nearly 40% of annual deaths. High levels of low- ...

    SBIR Phase I 2009 Department of Health and Human Services
  10. Search for Antithrombotic Compounds to Overcome Adverse Effects of Current Drugs

    Amount: $256,345.00

    DESCRIPTION (provided by applicant): Uncontrolled blood clotting or thrombosis is a primary cause of death in the US and developed world. Fatal or debilitating blood clots occur in the three major dis ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government